Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05388669 · OUTCOME

Change From Baseline in Therapy Administration Satisfaction Questionnaire (TASQ) as Assessed Over Time

A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer · Source last updated 2026-08-31

This outcome was registered, but no numerical results were posted in the captured record.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
From baseline (Day 1, Cycle 1) to 3 years 4 months (each cycle of 28 days)

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
anticipated Posting Date
2026-12
denom Units Selected
Participants
reporting Status
NOT_POSTED
time Frame
From baseline (Day 1, Cycle 1) to 3 years 4 months (each cycle of 28 days)
title
Change From Baseline in Therapy Administration Satisfaction Questionnaire (TASQ) as Assessed Over Time
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice